PCRX Quote, Financials, Valuation and Earnings

Edgewise Therapeutics has a net margin of 8.57% compared to Pacira BioSciences's net margin of --. Pacira BioSciences's return on equity of -11.94% beat Edgewise Therapeutics's return on equity of --.

Pacira BioSciences has a consensus price target of $36.00, signalling upside risk potential of 39.97%. On the other hand Edgewise Therapeutics has an analysts' consensus of $42.78 which suggests that it could grow by 188.26%. Given that Edgewise Therapeutics has higher upside potential than Pacira BioSciences, analysts believe Edgewise Therapeutics is more attractive than Pacira BioSciences.

Pacira BioSciences has a beta of 0.706, which suggesting that the stock is 29.437% less volatile than S&P 500. In comparison Edgewise Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Pacira BioSciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edgewise Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pacira BioSciences pays -- of its earnings as a dividend. Edgewise Therapeutics pays out -- of its earnings as a dividend.

Pacira BioSciences quarterly revenues are $187.3M, which are larger than Edgewise Therapeutics quarterly revenues of --. Pacira BioSciences's net income of $16M is higher than Edgewise Therapeutics's net income of -$39.7M. Notably, Pacira BioSciences's price-to-earnings ratio is 11.70x while Edgewise Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pacira BioSciences is 1.79x versus -- for Edgewise Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of 8.57% compared to Pacira BioSciences's net margin of 24.22%. Pacira BioSciences's return on equity of -11.94% beat Regeneron Pharmaceuticals's return on equity of 15.78%.

Pacira BioSciences has a consensus price target of $36.00, signalling upside risk potential of 39.97%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $850.21 which suggests that it could grow by 41.08%. Given that Regeneron Pharmaceuticals has higher upside potential than Pacira BioSciences, analysts believe Regeneron Pharmaceuticals is more attractive than Pacira BioSciences.

Pacira BioSciences has a beta of 0.706, which suggesting that the stock is 29.437% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.437, suggesting its less volatile than the S&P 500 by 56.337%.

Pacira BioSciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0.15% to investors and pays a quarterly dividend of $0.88 per share. Pacira BioSciences pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

Pacira BioSciences quarterly revenues are $187.3M, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3.8B. Pacira BioSciences's net income of $16M is lower than Regeneron Pharmaceuticals's net income of $917.7M. Notably, Pacira BioSciences's price-to-earnings ratio is 11.70x while Regeneron Pharmaceuticals's PE ratio is 15.74x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pacira BioSciences is 1.79x versus 4.88x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Sarepta Therapeutics has a net margin of 8.57% compared to Pacira BioSciences's net margin of 24.16%. Pacira BioSciences's return on equity of -11.94% beat Sarepta Therapeutics's return on equity of 20.83%.

Pacira BioSciences has a consensus price target of $36.00, signalling upside risk potential of 39.97%. On the other hand Sarepta Therapeutics has an analysts' consensus of $147.33 which suggests that it could grow by 143.77%. Given that Sarepta Therapeutics has higher upside potential than Pacira BioSciences, analysts believe Sarepta Therapeutics is more attractive than Pacira BioSciences.

Pacira BioSciences has a beta of 0.706, which suggesting that the stock is 29.437% less volatile than S&P 500. In comparison Sarepta Therapeutics has a beta of 0.930, suggesting its less volatile than the S&P 500 by 6.993%.

Pacira BioSciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pacira BioSciences pays -- of its earnings as a dividend. Sarepta Therapeutics pays out -- of its earnings as a dividend.

Pacira BioSciences quarterly revenues are $187.3M, which are smaller than Sarepta Therapeutics quarterly revenues of $658.4M. Pacira BioSciences's net income of $16M is lower than Sarepta Therapeutics's net income of $159M. Notably, Pacira BioSciences's price-to-earnings ratio is 11.70x while Sarepta Therapeutics's PE ratio is 26.51x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pacira BioSciences is 1.79x versus 3.54x for Sarepta Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals has a net margin of 8.57% compared to Pacira BioSciences's net margin of 31.35%. Pacira BioSciences's return on equity of -11.94% beat Vertex Pharmaceuticals's return on equity of -3.23%.

Pacira BioSciences has a consensus price target of $36.00, signalling upside risk potential of 39.97%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $500.32 which suggests that it could grow by 1.31%. Given that Pacira BioSciences has higher upside potential than Vertex Pharmaceuticals, analysts believe Pacira BioSciences is more attractive than Vertex Pharmaceuticals.

Pacira BioSciences has a beta of 0.706, which suggesting that the stock is 29.437% less volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.504, suggesting its less volatile than the S&P 500 by 49.617%.

Pacira BioSciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pacira BioSciences pays -- of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.

Pacira BioSciences quarterly revenues are $187.3M, which are smaller than Vertex Pharmaceuticals quarterly revenues of $2.9B. Pacira BioSciences's net income of $16M is lower than Vertex Pharmaceuticals's net income of $913M. Notably, Pacira BioSciences's price-to-earnings ratio is 11.70x while Vertex Pharmaceuticals's PE ratio is 26.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pacira BioSciences is 1.79x versus 11.62x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.